An interventional study of Nebivolol and Hydrochlorothiazide in Hypertension, sponsored by InVasc Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-05-05.
Sponsored by InVasc Therapeutics, Inc. · Not applicable, Interventional, and Diagnostic
The main purpose of this study is to evaluate the effects of Nebivolol and Hydrochlorothiazide on blood pressure in African Americans with high blood pressure.
Many blood pressure medications are not effective in African American men and women. The two lower chambers of the heart contract to pump blood to the body. The lower chambers have to relax so they can refill with blood to pump out again. Many patients with high blood pressure have stiffness in the lower chambers which prevents the heart from relaxing so it can properly fill with blood. Some patients with the stiffness in the lower chambers of the heart will develop heart failure.
The study is to test whether or not Nebivolol (Bystolic)and a diuretic Hydrochlorothiazide (HCTZ) will help the heart relax so the heart can properly fill and prevent stiffness of the lower heart chambers.
6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.
This study's enrollment of 40 is below the median of 90 across 4,995 interventional studies indexed under Hypertension.
Browse Hypertension studies →InVasc Therapeutics, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Nebivolol to reach blood pressure control
Drug: Nebivolol
Hydrochlorothiazide for blood pressure control
Drug: Hydrochlorothiazide
5mg/day with increase to 10 mg/day to reach blood pressure \<140/90
Also known as: Bystolic
Hydrochlorothiazide 25 mg/day
Also known as: HCTZ
Changes in systolic and diastolic blood pressure after treatment with nebivolol and reaching normal blood pressure <140/90
Time frame: Every visit for 25 weeks (9 study visits)
Differences after nebivolol treatment on diastolic function as measured by tissue doppler imaging (ECHO), arterial compliance and stiffness and vascular nitric oxide availability determined by neutrophil function
Time frame: At the begining and end of study
This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
InVasc Therapeutics, Inc.